Tax Court Backs Medtronic In Transfer-Payment Dispute
This article was originally published in The Gray Sheet
Executive Summary
The ruling means a larger portion of the company’s earnings can be taxed at the lower rate applied to foreign corporations.
You may also be interested in...
Boston Scientific Plans IRS Settlement
Boston Sci plans to pay $275m to settle transfer-pricing disputes with the US Internal Revenue Service. A financial analyst views the settlement as a win for the company because it’s well below what the IRS initially sought.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.